PE43398A1 - Quinoxalinadionas - Google Patents

Quinoxalinadionas

Info

Publication number
PE43398A1
PE43398A1 PE1997000162A PE00016297A PE43398A1 PE 43398 A1 PE43398 A1 PE 43398A1 PE 1997000162 A PE1997000162 A PE 1997000162A PE 00016297 A PE00016297 A PE 00016297A PE 43398 A1 PE43398 A1 PE 43398A1
Authority
PE
Peru
Prior art keywords
formula
alkyl
compounds
piridinyl
seizure
Prior art date
Application number
PE1997000162A
Other languages
English (en)
Inventor
Alan Stobie
Charles Eric Mowbray
David John Bull
Christopher Lee Carr
Elisabeth Colette Louise Gautier
Michael Jonathan Fray
Original Assignee
Pfizer Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Res & Dev filed Critical Pfizer Res & Dev
Publication of PE43398A1 publication Critical patent/PE43398A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Luminescent Compositions (AREA)
  • Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

SE REFIEREN A LOS COMPUESTOS DE FORMULA (I) Y A LOS COMPUESTOS INTERMEDIOS DE FORMULA (II), EN DONDE: R ES TRIAZOL O TETRAZOL (CON 1 o 2 SUSTITUYENTES DE ALQUILO C1-C4, ALCOXI C1-C4, FENILO OPCIONALMENTE SUSTITUIDO o HET, ENTRE OTROS), O ES PIRIDINILO O PIRIMIDINILO; HET ES PIRIDINILO O IMIDAZOLILO, ENTRE OTROS, LOS CUALES SE ENCUENTRAN OPCIONALMENTE SUSTITUIDOS Y OPCIONALMENTE CONDENSADOS CON BENCENO; R1 Y R2 SON Cl o ALQUILO C1-C4, ENTRE OTROS; R5 Y R6 SON ALQUILO C1-C4, BENCILO OPCIONALMENTE SUSTITUIDO, O TOMADOS JUNTOS R5 Y R6 FORMAN ALQUILENO C1-C6, CH(FENILO), CH(4-METOXIFENILO) O CH(3,4-DIMETOXIFENILO); SIENDO EL COMPUESTO DE FORMULA (I) PREFERIDO LA SAL SODICA O LA BASE LIBRE R-(-)-6,7-DICLORO-5-[3-METOXIMETIL-5-(3-PIRIDINIL)-4H-1,2,4-TRIAZOL-4-IL]-2,3(1H,4H)-QUINOXALINADIONA. TAMBIEN SE REFIERE AL PROCEDIMIENTO DE PREPARACION DE (I), QUE COMPRENDE LA HIDROLISIS ACIDA O BASICA DEL COMPUESTO DE FORMULA (II). LOS COMPUESTOS OBTENIDOS ACTUAN COMO ANTAGONISTAS SELECTIVOS DEL RECEPTOR N-METIL-D-ASPARTATO (NMDA), SIENDO UTILES EN EL TRATAMIENTO DE TRANSTORNOS NEURODEGENERATIVOS AGUDOS Y CRONICOS, COMO ANTICONVULSIVOS, ANSIOLITICOS, ENTRE OTROS
PE1997000162A 1996-03-09 1997-03-06 Quinoxalinadionas PE43398A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9605027.3A GB9605027D0 (en) 1996-03-09 1996-03-09 Quinoxalinediones

Publications (1)

Publication Number Publication Date
PE43398A1 true PE43398A1 (es) 1998-08-29

Family

ID=10790134

Family Applications (2)

Application Number Title Priority Date Filing Date
PE1997000162A PE43398A1 (es) 1996-03-09 1997-03-06 Quinoxalinadionas
PE1998000128A PE58199A1 (es) 1996-03-09 1998-02-23 Quinoxalinadionas

Family Applications After (1)

Application Number Title Priority Date Filing Date
PE1998000128A PE58199A1 (es) 1996-03-09 1998-02-23 Quinoxalinadionas

Country Status (42)

Country Link
US (1) US6376490B1 (es)
EP (1) EP0885212B1 (es)
JP (1) JP3110467B2 (es)
KR (1) KR100288099B1 (es)
CN (1) CN1103770C (es)
AP (1) AP767A (es)
AR (1) AR006119A1 (es)
AT (1) ATE208773T1 (es)
AU (1) AU717972B2 (es)
BG (1) BG63340B1 (es)
BR (1) BR9707851A (es)
CA (1) CA2248366C (es)
CO (1) CO4770976A1 (es)
CZ (1) CZ292792B6 (es)
DE (1) DE69708269T2 (es)
DK (1) DK0885212T3 (es)
DZ (1) DZ2188A1 (es)
EA (1) EA001730B1 (es)
ES (1) ES2163742T3 (es)
GB (1) GB9605027D0 (es)
HN (1) HN1998000034A (es)
HR (1) HRP970132A2 (es)
HU (1) HUP9900975A3 (es)
ID (1) ID18112A (es)
IL (1) IL125491A (es)
IS (1) IS4811A (es)
MA (1) MA26422A1 (es)
NO (1) NO984058L (es)
NZ (1) NZ331060A (es)
OA (1) OA10850A (es)
PE (2) PE43398A1 (es)
PL (1) PL329032A1 (es)
PT (1) PT885212E (es)
SI (1) SI0885212T1 (es)
SK (1) SK283467B6 (es)
TN (1) TNSN97044A1 (es)
TR (1) TR199801782T2 (es)
TW (1) TW454004B (es)
UY (1) UY24482A1 (es)
WO (1) WO1997032873A1 (es)
YU (2) YU39698A (es)
ZA (1) ZA971987B (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9808126A (pt) * 1997-02-27 2000-03-08 Pfizer Quinoxalinodionas
AP982A (en) * 1997-02-27 2001-07-16 Pfizer Quinoxalinediones.
US6340758B1 (en) * 1997-05-16 2002-01-22 Warner-Lambert Company Conformationally semi-constrained quinoxaline 2,3-diones as neuroprotective agents
DE10005150A1 (de) 2000-02-07 2001-08-09 Merck Patent Gmbh Verfahren zur Herstellung von 5-Arylnicotinaldehyden
RU2002133666A (ru) * 2000-05-19 2007-05-10 Мерк Патент ГмбХ (DE) Производные триазола
US7732162B2 (en) 2003-05-05 2010-06-08 Probiodrug Ag Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases
WO2005006945A2 (en) * 2003-07-03 2005-01-27 The Salk Institute For Biological Studies Methods for treating neural disorders and compounds useful therefor
MY145368A (en) * 2004-01-13 2012-01-31 Nissan Chemical Ind Ltd Aminoquinoxaline compounds and polyaminoquinoxaline compounds, and use thereof
CN1926647B (zh) 2004-02-06 2010-04-14 国立大学法人山口大学 储能装置用电极及其制造方法
JP2007223901A (ja) * 2004-03-24 2007-09-06 Takeda Chem Ind Ltd 複素環化合物およびその用途
US20060211739A1 (en) * 2005-02-08 2006-09-21 Arturo Perez-Medrano Use of selective P2X7 receptor antagonists
WO2007112347A1 (en) * 2006-03-28 2007-10-04 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
WO2008055945A1 (en) 2006-11-09 2008-05-15 Probiodrug Ag 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases
ATE554085T1 (de) 2006-11-30 2012-05-15 Probiodrug Ag Neue inhibitoren von glutaminylcyclase
US8603980B2 (en) 2007-01-16 2013-12-10 The Johns Hopkins University Glutamate receptor antagonists and methods of use
EP2117540A1 (en) 2007-03-01 2009-11-18 Probiodrug AG New use of glutaminyl cyclase inhibitors
JP5667440B2 (ja) 2007-04-18 2015-02-12 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤としてのチオ尿素誘導体
CN104370834B (zh) * 2007-05-17 2017-04-19 株式会社半导体能源研究所 三唑衍生物
SG178953A1 (en) 2009-09-11 2012-04-27 Probiodrug Ag Heterocylcic derivatives as inhibitors of glutaminyl cyclase
US9181233B2 (en) 2010-03-03 2015-11-10 Probiodrug Ag Inhibitors of glutaminyl cyclase
AU2011226074B2 (en) 2010-03-10 2015-01-22 Vivoryon Therapeutics N.V. Heterocyclic inhibitors of glutaminyl cyclase (QC, EC 2.3.2.5)
US8541596B2 (en) 2010-04-21 2013-09-24 Probiodrug Ag Inhibitors
ES2570167T3 (es) 2011-03-16 2016-05-17 Probiodrug Ag Derivados de benzimidazol como inhibidores de glutaminil ciclasa
JP2016507537A (ja) * 2013-02-07 2016-03-10 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung 置換アセチレン誘導体およびmGluR4の正のアロステリックモジュレーターとしてのそれらの使用
ES2812698T3 (es) 2017-09-29 2021-03-18 Probiodrug Ag Inhibidores de glutaminil ciclasa
CN111548320B (zh) * 2019-10-09 2023-03-24 贵州大学 一类1,3,4-噁二唑酰肼类化合物及其制备方法和应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0556393B1 (en) * 1990-11-06 2000-07-26 Yamanouchi Pharmaceutical Co. Ltd. Fused pyrazine derivative
DE4217952A1 (de) * 1992-05-30 1993-12-02 Basf Ag Chinoxalin-2,3(1H,4H)-dione
GB9418443D0 (en) 1994-09-13 1994-11-02 Pfizer Ltd Therapeutic agents
DE4439492A1 (de) * 1994-10-25 1996-05-02 Schering Ag Neue Chinoxalindionderivate, deren Herstellung und Verwendung in Arzneimitteln
BR9808126A (pt) * 1997-02-27 2000-03-08 Pfizer Quinoxalinodionas

Also Published As

Publication number Publication date
YU41199A (sh) 2001-09-28
GB9605027D0 (en) 1996-05-08
SK121498A3 (en) 2000-10-09
PE58199A1 (es) 1999-06-11
IL125491A (en) 2003-07-06
YU39698A (sh) 1999-03-04
DE69708269D1 (de) 2001-12-20
NO984058D0 (no) 1998-09-03
NO984058L (no) 1998-11-06
NZ331060A (en) 2000-01-28
KR19990087614A (ko) 1999-12-27
BG102760A (en) 1999-09-30
SK283467B6 (sk) 2003-08-05
OA10850A (en) 2001-08-16
AP767A (en) 1999-09-29
AR006119A1 (es) 1999-08-11
US6376490B1 (en) 2002-04-23
ATE208773T1 (de) 2001-11-15
AU2023197A (en) 1997-09-22
EP0885212A1 (en) 1998-12-23
IS4811A (is) 1998-07-27
ZA971987B (en) 1998-09-07
PT885212E (pt) 2002-02-28
DZ2188A1 (fr) 2002-12-02
DE69708269T2 (de) 2002-07-25
JPH11506123A (ja) 1999-06-02
JP3110467B2 (ja) 2000-11-20
CZ292792B6 (cs) 2003-12-17
HN1998000034A (es) 1999-02-09
IL125491A0 (en) 1999-03-12
HUP9900975A3 (en) 2001-12-28
WO1997032873A1 (en) 1997-09-12
KR100288099B1 (ko) 2001-05-02
TR199801782T2 (xx) 1998-12-21
DK0885212T3 (da) 2002-03-25
CA2248366C (en) 2002-06-04
EA199800702A1 (ru) 1999-04-29
UY24482A1 (es) 2000-09-29
ES2163742T3 (es) 2002-02-01
ID18112A (id) 1998-03-05
BR9707851A (pt) 1999-07-27
EP0885212B1 (en) 2001-11-14
MA26422A1 (fr) 2004-12-20
TNSN97044A1 (fr) 2005-03-15
CN1213369A (zh) 1999-04-07
TW454004B (en) 2001-09-11
CO4770976A1 (es) 1999-04-30
HUP9900975A2 (hu) 1999-07-28
BG63340B1 (bg) 2001-10-31
AU717972B2 (en) 2000-04-06
PL329032A1 (en) 1999-03-01
EA001730B1 (ru) 2001-08-27
AP9700947A0 (en) 1997-04-30
CZ286498A3 (cs) 1999-07-14
HRP970132A2 (en) 1998-06-30
CN1103770C (zh) 2003-03-26
CA2248366A1 (en) 1997-09-12
SI0885212T1 (en) 2002-02-28

Similar Documents

Publication Publication Date Title
PE43398A1 (es) Quinoxalinadionas
KR880013909A (ko) 고혈압 치료 화합물에 대한 테트라졸 중간체
AP2001002307A0 (en) B3 adrenergic receptor agonists and uses thereof.
MX9702601A (es) AGONISTAS beta-ADRENERGICOS HETEROCICLICOS.
WO2000067735A3 (en) USE OF SELECTIVE ANTAGONISTS OF THE α1b-ADRENERGIC RECEPTOR FOR IMPROVEMENT OF SEXUAL DYSFUNCTION
TR200001079T2 (tr) Bisiklik kinaz inhibitörleri.
PL361361A1 (en) Substituted 1-aminoalkyl-lactams and their use as muscarinic receptor antagonists
PE20070355A1 (es) Antagonistas de cgrp seleccionados y procedimientos para su preparacion
NO20025640D0 (no) Substituerte 1-aminoalkyl-laktamer og deres anvendelse som muscarin-reseptor-antagonister
DE2967005D1 (en) 2-alkoxycarbonylamino benzimidazoles having a halogen-containing substituent, their preparation and their use as parasiticides
DK83684D0 (da) Substituerede diazolylalkylcarbinoler, deres fremstilling og anvendelse som antimykotiske midler
WO2001036425A3 (de) Imidazolverbindungen als phosphodiesterase vii-hemmer
ID23954A (id) Tetrahidrogama-karbolin
PE20001456A1 (es) Compuestos calcioliticos
ATE284871T1 (de) Bicyclische vasopressin-agoniste
IL70718A0 (en) Triazole derivatives,their preparation and pharmaceutical compositions containing them
PT1019048E (pt) Uso de um antagonista do receptor da angiotensina ii para a preparacao de farmacos para aumentar a taxa de sobrevivencia de pacientes sujeitos a transplante renal
DE69221634D1 (de) 5-Piperazinylalkyl)-1,5-Benzothiazepinone verwendbar als Calciumantagonisten
ES8504750A1 (es) Un procedimiento para preparar compuestos heterociclicos
NZ309036A (en) pyrazole or triazole - oxybenzyl alkoxyacrylic acid esters, process for producing them and their use as fungicides
CO5261532A1 (es) Compuestos heterociclicos sililados, procedimiento para la preparacion de estos y composicion farmaceutica que los contiene
EA200100150A1 (ru) Биспиперидины в качестве противотромботических агентов
RU2007146731A (ru) Тромбин-ингибирующие производные 2-оксо-1, 2, 5, 6-тетрагидропиридина
PE20020732A1 (es) Profarmacos de compuestos de azol solubles en agua
TH52364A (th) ปรปักษ์ของตัวรับเบนซอกซาซิโนนโดพามีน d4

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed